StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Kyverna Therapeutics's total assets was $189.44M at Sep 30, 2026. For fiscal 2025 it was $293.83M, down 3.6% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$293.83M-3.6%
FY2024Dec 31, 2024$304.65M+305.1%
FY2023Dec 31, 2023$75.20M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$189.44M+1.2%
Q2 FY2026Jun 30, 2026$219.82M-3.0%
Q1 FY2026Mar 31, 2026$257.02M-1.4%
Q4 FY2025Dec 31, 2025$293.83M-3.6%
Q3 FY2025Sep 30, 2025$187.16M-44.8%
Q2 FY2025Jun 30, 2025$226.51M-37.6%
Q1 FY2025Mar 31, 2025$260.66M-33.2%
Q4 FY2024Dec 31, 2024$304.65M+305.1%
Q3 FY2024Sep 30, 2024$339.20M–
Q2 FY2024Jun 30, 2024$363.12M–
Q1 FY2024Mar 31, 2024$389.98M–
Q4 FY2023Dec 31, 2023$75.20M–

More Kyverna Therapeutics figures

See a number that looks wrong?